Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis

NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD

2.25  0 (0%)

Fundamental Rating

3

SERA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. The financial health of SERA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SERA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SERA had negative earnings in the past year.
In the past year SERA has reported a negative cash flow from operations.
In the past 5 years SERA always reported negative net income.
In the past 5 years SERA always reported negative operating cash flow.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -27.91%, SERA is doing good in the industry, outperforming 69.58% of the companies in the same industry.
Looking at the Return On Equity, with a value of -34.80%, SERA is in the better half of the industry, outperforming 74.68% of the companies in the same industry.
Industry RankSector Rank
ROA -27.91%
ROE -34.8%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 8.70%, SERA is in the better half of the industry, outperforming 72.68% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SERA has been increased compared to 1 year ago.
SERA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SERA has an improved debt to assets ratio.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

SERA has an Altman-Z score of -2.02. This is a bad value and indicates that SERA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SERA (-2.02) is comparable to the rest of the industry.
There is no outstanding debt for SERA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.02
ROIC/WACCN/A
WACC9.8%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.02 indicates that SERA has no problem at all paying its short term obligations.
SERA has a Current ratio of 2.02. This is in the lower half of the industry: SERA underperforms 74.86% of its industry peers.
A Quick Ratio of 2.02 indicates that SERA has no problem at all paying its short term obligations.
The Quick ratio of SERA (2.02) is worse than 73.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.02
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

SERA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.27%, which is quite good.
The Revenue for SERA has decreased by -74.84% in the past year. This is quite bad
Measured over the past years, SERA shows a quite strong growth in Revenue. The Revenue has been growing by 14.00% on average per year.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)-74.84%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%

3.2 Future

SERA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.82% yearly.
The Revenue is expected to grow by 195.78% on average over the next years. This is a very strong growth
EPS Next Y8.3%
EPS Next 2Y1.56%
EPS Next 3Y2.04%
EPS Next 5Y8.82%
Revenue Next Year236.36%
Revenue Next 2Y326.4%
Revenue Next 3Y293.45%
Revenue Next 5Y195.78%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.56%
EPS Next 3Y2.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SERA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERA PROGNOSTICS INC-A

NASDAQ:SERA (8/20/2025, 8:23:55 PM)

2.25

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners73.39%
Inst Owner Change-7.76%
Ins Owners2.95%
Ins Owner Change10.53%
Market Cap84.76M
Analysts85
Price TargetN/A
Short Float %3.84%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.31%
Min EPS beat(2)-2.12%
Max EPS beat(2)14.75%
EPS beat(4)2
Avg EPS beat(4)3.3%
Min EPS beat(4)-6.95%
Max EPS beat(4)14.75%
EPS beat(8)6
Avg EPS beat(8)8.45%
EPS beat(12)10
Avg EPS beat(12)12.34%
EPS beat(16)10
Avg EPS beat(16)-6.08%
Revenue beat(2)1
Avg Revenue beat(2)1.72%
Min Revenue beat(2)-53.43%
Max Revenue beat(2)56.86%
Revenue beat(4)1
Avg Revenue beat(4)-33.86%
Min Revenue beat(4)-72.32%
Max Revenue beat(4)56.86%
Revenue beat(8)2
Avg Revenue beat(8)-38.58%
Revenue beat(12)3
Avg Revenue beat(12)-30.55%
Revenue beat(16)4
Avg Revenue beat(16)-28.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.65%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 737.02
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS2.52
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.91%
ROE -34.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.7%
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.96%
Cap/Sales 342.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 2.02
Altman-Z -2.02
F-Score3
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)83.45%
Cap/Depr(5y)92.8%
Cap/Sales(3y)588.1%
Cap/Sales(5y)777.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y8.3%
EPS Next 2Y1.56%
EPS Next 3Y2.04%
EPS Next 5Y8.82%
Revenue 1Y (TTM)-74.84%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%
Revenue Next Year236.36%
Revenue Next 2Y326.4%
Revenue Next 3Y293.45%
Revenue Next 5Y195.78%
EBIT growth 1Y2.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.68%
OCF growth 3YN/A
OCF growth 5YN/A